Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
StemCells Inc Announces Human Neural Stem Cells Restore Memory In Models Of Alzheimer's Disease
StemCells Inc announced preclinical data demonstrating that its human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease (AD). The data was presented at the Alzheimer's Association International Conference 2012 in Vancouver, Canada. The study results showed that transplanting the cells into a specific region of the brain, the hippocampus, statistically increased memory in two different animal models. The hippocampus is critically important to the control of memory and is severely impacted by the pathology of AD. Specifically, hippocampal synaptic density is reduced in AD and correlates with memory loss. The researchers observed increased synaptic density and improved memory post transplantation. Importantly, these results did not require reduction in beta amyloid or tau that accumulate in the brains of patients with AD and account for the pathological hallmarks of the disease. The research was conducted in collaboration with a world-renowned in AD, Frank LaFerla, Ph.D., Director of the University of California, Irvine (UCI) Institute for Memory Impairments and Neurological Disorders (UCI MIND), and Chancellor's Professor, Neurobiology and Behavior in the School of Biological Sciences at UCI. Matthew Blurton-Jones, Ph.D., Assistant Professor, Neurobiology and Behavior at UCI, presented the study results.
Latest Developments for StemCells Inc
- StemCells Inc Reports Positive Interim Data From Spinal Cord Injury Trial
- StemCells Inc's Milestone Clinical Trial in Pelizaeus-Merzbacher Disease Shows Evidence of Myelination Following Human Neural Stem Cell Transplantation
- StemCells Inc Receives FDA Authorization For Age-Related Macular Degeneration Clinical Trial
- StemCells Inc Announces Publication Of Preclinical Data Demonstrating Human Neural Stem Cells Preserve Vision
Latest Key Developments in Biotechnology
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Norda ASA Plans Delisting from Oslo Stock Exchange
- Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
- Share this
- Link this
- Digg this


Follow Reuters